Literature DB >> 8897011

Association of IA-2 autoantibodies with HLA DR4 phenotypes in IDDM.

S Genovese1, R Bonfanti, E Bazzigaluppi, V Lampasona, E Benazzi, E Bosi, G Chiumello, E Bonifacio.   

Abstract

Insulin, glutamate decarboxylase (GAD) and the protein tyrosine phosphatase-like molecule IA-2 are major targets of humoral autoimmunity in insulin-dependent diabetes mellitus (IDDM). These autoantibodies are heterogeneous with respect to age and patient human leukocyte antigen (HLA) phenotype. We have previously demonstrated that GAD and IA-2 antibodies potentially identify different subsets of IDDM patients. The aim of this study was to determine whether GAD and IA-2 autoantibodies were associated with different HLA DR phenotypes. We studied 160 patients with IDDM onset before age 16 years. At disease onset serum was tested for GAD and IA-2 antibodies by immunoprecipitation by in vitro-translated 35S-methionine labelled recombinant proteins. IA-2 antibodies were significantly associated with HLA DR4: 67 (86%) of 78 patients with HLA DR4 vs 31 (38%) of 82 non-DR4 patients had IA-2 antibodies (Pc < 0.0001) and IA-2 antibody levels were higher in patients with HLA DR4 (Pc < 0.0001). In contrast, GAD antibodies were more prevalent (Pc < 0.05) and antibody levels highest (Pc < 0.01) in patients with HLA DR3 phenotypes. These data provide further evidence that, in IDDM, production and titre of major autoantibody specificities are associated with HLA class II alleles.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8897011     DOI: 10.1007/BF02658510

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  17 in total

1.  Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase.

Authors:  S Baekkeskov; H J Aanstoot; S Christgau; A Reetz; M Solimena; M Cascalho; F Folli; H Richter-Olesen; P De Camilli; P D Camilli
Journal:  Nature       Date:  1990-09-13       Impact factor: 49.962

2.  Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies.

Authors:  E Bonifacio; V Lampasona; S Genovese; M Ferrari; E Bosi
Journal:  J Immunol       Date:  1995-12-01       Impact factor: 5.422

3.  HLA-associated insulin autoantibody formation in newly diagnosed type I diabetic patients.

Authors:  A G Ziegler; E Standl; E Albert; H Mehnert
Journal:  Diabetes       Date:  1991-09       Impact factor: 9.461

4.  Insulin antibodies in insulin-dependent diabetics before insulin treatment.

Authors:  J P Palmer; C M Asplin; P Clemons; K Lyen; O Tatpati; P K Raghu; T L Paquette
Journal:  Science       Date:  1983-12-23       Impact factor: 47.728

5.  Antibodies to islet 37k antigen, but not to glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity.

Authors:  M R Christie; S Genovese; D Cassidy; E Bosi; T J Brown; M Lai; E Bonifacio; G F Bottazzo
Journal:  Diabetes       Date:  1994-10       Impact factor: 9.461

6.  Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases.

Authors:  D U Rabin; S M Pleasic; J A Shapiro; H Yoo-Warren; J Oles; J M Hicks; D E Goldstein; P M Rae
Journal:  J Immunol       Date:  1994-03-15       Impact factor: 5.422

7.  Relationship of the 37,000- and 40,000-M(r) tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512).

Authors:  M A Payton; C J Hawkes; M R Christie
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

8.  HLA heterogeneity of insulin-dependent diabetes mellitus at diagnosis. The Pittsburgh IDDM study.

Authors:  M S Eberhardt; D K Wagener; T J Orchard; R E LaPorte; D E Cavender; B S Rabin; R W Atchison; L H Kuller; A L Drash; D J Becker
Journal:  Diabetes       Date:  1985-12       Impact factor: 9.461

9.  Disease sensitivity and specificity of 52 assays for glutamic acid decarboxylase antibodies. The Second International GADAB Workshop.

Authors:  R S Schmidli; P G Colman; E Bonifacio
Journal:  Diabetes       Date:  1995-06       Impact factor: 9.461

10.  HLA-DQ genotypes are associated with autoimmunity to glutamic acid decarboxylase in insulin-dependent diabetes mellitus patients.

Authors:  S W Serjeantson; J Court; I R Mackay; B Matheson; M J Rowley; T Tuomi; J D Wilson; P Zimmet
Journal:  Hum Immunol       Date:  1993-10       Impact factor: 2.850

View more
  20 in total

Review 1.  Genetic predisposition to IDDM.

Authors:  S Caillat-Zucman; J F Bach
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

2.  Islet cell, thyroid, adrenal and celiac disease related autoantibodies in patients with Type 1 diabetes from Sri Lanka.

Authors:  L D K E Premawardhana; C N Wijeyaratne; S Chen; M Wijesuriya; U Illangasekera; H Brooking; M Amoroso; J Jeffreys; J Bolton; J H Lazarus; J Furmaniak; B Rees Smith
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

3.  IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71).

Authors:  G F Bottazzo; E Bosi; C A Cull; E Bonifacio; M Locatelli; P Zimmet; I R Mackay; R R Holman
Journal:  Diabetologia       Date:  2005-03-12       Impact factor: 10.122

4.  HLA-DQB1 genotypes, islet antibodies and beta cell function in the classification of recent-onset diabetes among young adults in the nationwide Diabetes Incidence Study in Sweden.

Authors:  E Bakhtadze; H Borg; G Stenström; P Fernlund; H J Arnqvist; A Ekbom-Schnell; J Bolinder; J W Eriksson; S Gudbjörnsdottir; L Nyström; L C Groop; G Sundkvist
Journal:  Diabetologia       Date:  2006-05-31       Impact factor: 10.122

5.  Autoimmunity to glutamic acid decarboxylase in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).

Authors:  P Klemetti; P Björses; T Tuomi; J Perheentupa; J Partanen; N Rautonen; A Hinkkanen; J Ilonen; O Vaarala
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

6.  The effect of HLA class II, insulin and CTLA4 gene regions on the development of humoral beta cell autoimmunity.

Authors:  Robert Hermann; A P Laine; R Veijola; T Vahlberg; S Simell; J Lähde; O Simell; M Knip; J Ilonen
Journal:  Diabetologia       Date:  2005-07-16       Impact factor: 10.122

7.  Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes.

Authors:  K Decochez; I Truyen; B van der Auwera; I Weets; E Vandemeulebroucke; I H de Leeuw; B Keymeulen; C Mathieu; R Rottiers; D G Pipeleers; F K Gorus
Journal:  Diabetologia       Date:  2005-03-09       Impact factor: 10.122

8.  Disease-associated autoantibodies and HLA-DQB1 genotypes in children with newly diagnosed insulin-dependent diabetes mellitus (IDDM). The Childhood Diabetes in Finland Study Group.

Authors:  E Sabbah; K Savola; P Kulmala; H Reijonen; R Veijola; P Vähäsalo; J Karjalainen; J Ilonen; H K Akerblom; M Knip
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

9.  The effect of the MHC locus on autoantibodies in type 1 diabetes.

Authors:  H-Q Qu; C Polychronakos
Journal:  J Med Genet       Date:  2009-05-07       Impact factor: 6.318

10.  Autoantibodies to islet antigen-2 are associated with HLA-DRB1*07 and DRB1*09 haplotypes as well as DRB1*04 at onset of type 1 diabetes: the possible role of HLA-DQA in autoimmunity to IA-2.

Authors:  A J K Williams; R J Aitken; M A-M Chandler; K M Gillespie; V Lampasona; P J Bingley
Journal:  Diabetologia       Date:  2008-05-27       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.